Ellagic Acid Attenuates Doxorubicin-induced Cardiomyocyte Ferroptosis Via Nuclear Factor Erythroid 2-Related Factor 2 Signaling
Drug Research · 01.07.2026 · 76 (04/06) · 145-158
DOI: 10.1055/a-2873-4789 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Research, erschienen am 01.07.2026. Verfasst von Rong Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Wuhan Fourth Hospital, Wuhan, Department of Cardiology, China, Hubei. Hauptthemen laut MEDLINE: Ellagic Acid, Ferroptosis, Doxorubicin, Myocytes, Cardiac.
Abstract (Originalsprache)
AbstractDoxorubicin, a widely used chemotherapeutic agent, is clinically limited by its dose-dependent cardiotoxicity, in which cardiomyocyte ferroptosis has recently been identified as a critical pathogenic mechanism. Consequently, targeting myocardial ferroptosis has emerged as a promising strategy to reduce doxorubicin-induced cardiac injury. Ellagic acid, a naturally occurring polyphenolic compound, possesses potent antioxidant and anti-inflammatory properties that contribute to its cytoprotective effects. This study aimed to investigate the protective role of ellagic acid against doxorubicin-induced cardiomyocyte ferroptosis and elucidate its underlying mechanisms. Using H9C2 cells and human-induced pluripotent stem cell-derived cardiomyocytes, we established in vitro models of doxorubicin-induced cardiac ferroptosis. Ellagic acid treatment markedly upregulated the expression of anti-ferroptosis proteins, reduced reactive oxygen species accumulation, and alleviated lipid peroxidation, thereby suppressing doxorubicin-triggered ferroptosis. Moreover, the anti-ferroptosis effects of ellagic acid were validated in vivo. Mechanistically, these cardioprotective actions were mediated through the activation of the nuclear factor erythroid 2-related factor 2 signaling pathway. In conclusion, our findings identify ellagic acid as a novel nuclear factor erythroid 2-related factor 2 activator that protects against doxorubicin-induced cardiotoxicity by inhibiting ferroptosis in cardiomyocytes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Wuhan Fourth Hospital, Wuhan, Department of Cardiology, China, Hubei.
- Wuhan No.1 Hospital, Wuhan Hospital of Traditional Chinese and Western Medicine, Department of Cardiology, China, Wuhan, Hubei.
ORCID-Profile: Wei Li
Zitieren
APA
Li, R., Cheng, Z., & Li, W. (2026). Ellagic Acid Attenuates Doxorubicin-induced Cardiomyocyte Ferroptosis Via Nuclear Factor Erythroid 2-Related Factor 2 Signaling. Drug Research, 76(04/06), 145-158. https://doi.org/10.1055/a-2873-4789
Vancouver
Li R, Cheng Z, Li W. Ellagic Acid Attenuates Doxorubicin-induced Cardiomyocyte Ferroptosis Via Nuclear Factor Erythroid 2-Related Factor 2 Signaling. Drug Research. 2026;76(04/06):145-158. doi:10.1055/a-2873-4789
BibTeX
@article{Li2026,
author = {Li, Rong and Cheng, Zhong and Li, Wei},
title = {Ellagic Acid Attenuates Doxorubicin-induced Cardiomyocyte Ferroptosis Via Nuclear Factor Erythroid 2-Related Factor 2 Signaling},
journal = {Drug Research},
year = {2026},
volume = {76},
number = {04/06},
pages = {145--158},
doi = {10.1055/a-2873-4789}
}
EUVIMED